Source: International Congress 2016 – Pulmonary hypertension: the clinic II



Rating:

Share or cite this content

Citations should be made in the following way:
Paul A. Corris (Newcastle, United Kingdom), Paul A. Corris, Margaret Day, Maxsim Gibiansky, Yoona A. Kim, Lorenzo DiCarlo. A pilot study of digital feedback to guide therapeutic decisions in pulmonary hypertension. Eur Respir J 2016; 48: Suppl. 60, 2407

Member's Comments

No comment yet.

Related content which might interest you: Clinical trial design and new therapies for pulmonary arterial hypertension Source: Eur Respir J, 53 (1) 1801908; 10.1183/13993003.01908-2018 Year: 2019 A regional nurse study day using small group tutorials- A successful novel approach to publicising pulmonary hypertension Source: Annual Congress 2013 –Improving educational programmes for patients and multidisciplinary healthcare professionals Year: 2013 Treat-to-target approach in pulmonary arterial hypertension: a consensus-based proposal Source: Eur Respir Rev 2012 21:259-262 Year: 2012 Issues related to the management and therapy of paediatric pulmonary hypertension Source: Eur Respir Rev 2010 19: 331-339 Year: 2010 Optimal management of severe pulmonary arterial hypertension Source: Eur Respir Rev 2011; 20: 254-261 Year: 2011 Screening pulmonary hypertension by lung doppler signal: A proof-of-concept study Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Source: Eur Respir J 2009; 34: 231-242 Year: 2009 Use of a telemedicine application for training and follow up of patients with pulmonary arterial hypertension Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 Pulmonary hypertension: new guidelines for therapy Source: Annual Congress 2007 - PG19 - Pulmonary vascular disorders: diagnosis and treatment Year: 2007 Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension Source: Eur Respir J, 50 (2) 1700889; 10.1183/13993003.00889-2017 Year: 2017 Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations Source: Eur Respir Rev, 28 (154) 190050; 10.1183/16000617.0050-2019 Year: 2019 Challenges in the diagnosis and treatment of pulmonary arterial hypertension Source: Eur Respir Rev 2012 21: 313-320 Year: 2012 Paediatric pulmonary hypertension: monitoring progress and identifying unmet needs Source: Eur Respir Rev 2009; 18: 18-23 Year: 2009 Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Optimising the management of pulmonary arterial hypertension patients: emergency treatments Source: Eur Respir Rev 2010 19: 204-211 Year: 2010 Self-reported adherence to pulmonary hypertension medications: Preliminary results from a longitudinal cohort study Source: International Congress 2014 – Qualitative and quantitative research that contributes to respiratory nursing practice Year: 2014 Treatment options for paediatric pulmonary arterial hypertension Source: Eur Respir Rev 2010 19: 321-330 Year: 2010 Dipyridamole as adjuvant therapy in patients with pulmonary arterial hypertension. A pilot study Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007 Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management Source: Eur Respir J, 53 (1) 1801916; 10.1183/13993003.01916-2018 Year: 2019